HomeBiotechnology

Biotechnology

Latest news, analysis, and insights from ASX biotechnology companies

Racura Oncology Demonstrates Key Equivalence for Reformulated Bisantrene Anti-Cancer Drug
Lead storyBiotechnology

Racura Oncology Demonstrates Key Equivalence for Reformulated Bisantrene Anti-Cancer Drug

Racura Oncology confirms reformulated bisantrene matches legacy drug exposure, supporting plans for a Phase 2b/3 AML trial.

Latest Stories — SECTOR DESK

Advertisement
Clarity Pharmaceuticals Granted Breakthrough Therapy Designation for Prostate Cancer Copper Theranostic
Biotechnology

Clarity Pharmaceuticals Granted Breakthrough Therapy Designation for Prostate Cancer Copper Theranostic

Clarity Pharmaceuticals wins FDA breakthrough status for prostate cancer PET agent 64Cu-SAR-bisPSMA, a major milestone for its copper theranostic program.

BlinkLab Reports Positive Results from Smartphone-Based Study into Genetic Autism
Biotechnology

BlinkLab Reports Positive Results from Smartphone-Based Study into Genetic Autism

BlinkLab reports positive SHANK2 autism study results, with its smartphone test detecting significant differences in brain and sensorimotor measures.

EVE Health Group Signs Australian Pharmacy Deal for Men's Health Range
Biotechnology

EVE Health Group Signs Australian Pharmacy Deal for Men's Health Range

EVE Health signs Australian pharmacy deal for its men’s health range, retaining 75% of distributable profit in a capital-light route to market.

Immutep Reports Exposure-Dependent Inhibition of T-Cell-Driven Responses in IMP761 Phase I Study
Biotechnology

Immutep Reports Exposure-Dependent Inhibition of T-Cell-Driven Responses in IMP761 Phase I Study

Immutep’s IMP761 showed significant, exposure-dependent suppression of T-cell responses in Phase I, with no serious or severe adverse events.

Mayne Pharma Sells International Operations for $55.5m to Focus on US Business
Biotechnology

Mayne Pharma Sells International Operations for $55.5m to Focus on US Business

Mayne Pharma sells international operations for $55.5m, sharpening its focus on US Women’s Health, Dermatology and DistributeRx growth.

Pacific Edge Wins US Medicare Coverage for Cxbladder Triage Tests
Biotechnology

Pacific Edge Wins US Medicare Coverage for Cxbladder Triage Tests

Pacific Edge secures US Medicare coverage for Cxbladder tests, opening an estimated 1.14 million annual testing opportunities.

Radiopharm Theranostics and FDA Agree on Design of Phase 3 RAD101 Trial for Brain Metastases
Biotechnology

Radiopharm Theranostics and FDA Agree on Design of Phase 3 RAD101 Trial for Brain Metastases

Radiopharm Theranostics secures FDA agreement on pivotal Phase 3 RAD101 trial, advancing its brain metastasis imaging agent toward clinical validation.

INOVIQ Signs Agreement with Sonic Healthcare to Advance EXO-OC Ovarian Cancer Detection Test
Biotechnology

INOVIQ Signs Agreement with Sonic Healthcare to Advance EXO-OC Ovarian Cancer Detection Test

INOVIQ partners with Sonic Healthcare USA to validate its EXO-OC ovarian cancer test, advancing a potential US commercialisation pathway.